Elanco Animal HealthELAN
ELAN
About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Employees: 9,450
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 125
4% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $10.8M
0.88% more ownership
Funds ownership: 98.98% [Q4 2024] → 99.86% (+0.88%) [Q1 2025]
8% less funds holding
Funds holding: 386 [Q4 2024] → 357 (-29) [Q1 2025]
12% less capital invested
Capital invested by funds: $5.93B [Q4 2024] → $5.19B (-$739M) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
36% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 70
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
19%
upside
Avg. target
$17.67
24%
upside
High target
$18
26%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
UBS Andrea Alfonso | 26%upside $18 | Buy Maintained | 23 Jul 2025 |
Leerink Partners Daniel Clark | 26%upside $18 | Outperform Upgraded | 17 Jul 2025 |
Stifel Jonathan Block | 19%upside $17 | Buy Maintained | 2 Jul 2025 |
Financial journalist opinion
Based on 6 articles about ELAN published over the past 30 days
Neutral
PRNewsWire
5 days ago
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs
The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world Launch to begin immediately with product in market before the end of Q3 2025 GREENFIELD, Ind. , July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission.
Neutral
Zacks Investment Research
5 days ago
ELAN vs. USPH: Which Stock Is the Better Value Option?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investors a better bang for their buck right now?
Neutral
PRNewsWire
2 weeks ago
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
GREENFIELD, Ind. , July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025.
Positive
Reuters
3 weeks ago
Elanco's dog flu vaccine gets USDA nod
Elanco Animal Health said on Wednesday the U.S. Department of Agriculture (USDA) has approved its canine flu vaccine, which offers dogs protection against serious respiratory disease.
Neutral
PRNewsWire
3 weeks ago
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4 TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.
Neutral
PRNewsWire
3 weeks ago
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for accelerated global commercialisation of NUZ-001 [1] and significantly de-risks future global regulatory approval processes The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025 MELBOURNE, Australia , July 2, 2025 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans. This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001.
Positive
Benzinga
1 month ago
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.
Neutral
PRNewsWire
1 month ago
Elanco Releases 2024 Impact Report and Introduces New Framework
GREENFIELD, Ind. , June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them.
Neutral
PRNewsWire
1 month ago
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing authorization in the European Union in the next 60 days.
Positive
Zacks Investment Research
1 month ago
What Makes Elanco Animal Health (ELAN) a New Buy Stock
Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™